Q-omics provides the consensus-scored MIR548AC profile across patient tissues and cancer cell-line models. MIR548AC expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MIR548AC is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, MIR548AC RNA expression shows 9,427 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight SKCM, LUSC, and ESCA as cancer lineages where MIR548AC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR548AC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR548AC survival associations across molecular data types. MIR548AC RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR548AC RNA expression–survival associations across cancer types. High MIR548AC expression shows unfavorable associations in SKCM, BRCA, UCS and LGG, but favorable associations in LUAD and LAML. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MIR548AC RNA expression.
This table summarizes MIR548AC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR548AC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR548AC shows lower tumor expression in KIRC and higher tumor expression in LUSC, HNSC, LIHC, LUAD and KICH. The LUSC box plot shows higher MIR548AC RNA expression in tumor versus normal tissue (log2 FC = +0.603, t-test p < 0.001).
This table shows molecular features associated with MIR548AC in patient tissues and cancer cell lines. In patient samples, MIR548AC shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
